<code id='F540158042'></code><style id='F540158042'></style>
    • <acronym id='F540158042'></acronym>
      <center id='F540158042'><center id='F540158042'><tfoot id='F540158042'></tfoot></center><abbr id='F540158042'><dir id='F540158042'><tfoot id='F540158042'></tfoot><noframes id='F540158042'>

    • <optgroup id='F540158042'><strike id='F540158042'><sup id='F540158042'></sup></strike><code id='F540158042'></code></optgroup>
        1. <b id='F540158042'><label id='F540158042'><select id='F540158042'><dt id='F540158042'><span id='F540158042'></span></dt></select></label></b><u id='F540158042'></u>
          <i id='F540158042'><strike id='F540158042'><tt id='F540158042'><pre id='F540158042'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:explore    Page View:422

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In